TFE on Korea Invest Insights

Korea Quality Re-Rating Watch 2026-10-29: Daedeok, TFE, Dongkuk

Thu, 29 Oct 2026 16:30:00 +0900

1. Macro Dashboard

Indicator	Level	5-Day Change	Signal
KOSPI	5,882	+7.0%	5-day rally, internals weak
KOSDAQ	750.1	+0.2%	Flat
VIX	17.0	−12.7%	Calm
US 10Y	4.99%	+0.09pp	Stable
USD/KRW	1,338	+0.9%	Mild KRW softness
Brent	$110.0	−5.0%	Declining
DXY	102.1	+0.2%	Flat

Regime: Korea = Bear / US = Bull. KOSPI (200-DMA: 6,480) and KOSDAQ (200-DMA: 974) both sit well below their long-term averages. Market breadth at 20.6% of stocks above the 50-DMA — below the 25% Bear threshold — confirms the regime despite the headline index recovery. US indices (NASDAQ, S&P 500) remain above 200-DMA with VIX at 17 and HY OAS tightening to 3.18%; the Bull label holds. Korean rates are easing at the margin (KTB 3Y: 3.80%, KTB 10Y: 4.11%), but the spread story does not yet override the breadth signal.

2. Market Wrap

Source: KR Market Snapshot (2026-10-29). No same-day full close briefing was available; market character is derived from the DB snapshot.

Today’s session was broadly negative beneath the surface. Of 2,593 names tracked, 1,793 declined against 542 advances. The ADR proxy came in at 30.2 and the average stock return hit −1.59% — the kind of internal weakness that makes the KOSPI headline a poor guide to what actually happened.

Construction and energy led the selling. 대우건설 (047040.KS) fell 18.57%, 한화솔루션 (009830.KS) −11.61%, LG에너지솔루션 (373220.KS) −8.60%, and SK이노베이션 (096770.KS) −7.09%. Crucially, foreign and institutional investors were aligned sellers in these names — a coordinated exit that differs from ordinary two-sided rotation.

Financials and data infrastructure attracted buyers. KB금융 (105560.KS) +1.82% and 삼성화재해상보험 (000810.KS) +2.20% were foreign net-buy names. Domestically, institutions accumulated 삼성SDI (006400.KS), 삼성생명 (032830.KS), 신한지주 (055550.KS), and 현대모비스 (012330.KS). 한화비전 (489790.KS) surged 22.14% on institutional buying against foreign selling — the day’s strongest single-name momentum. 케이아이엔엑스 (093320.KQ) +13.28% was another institutional pick in the data infrastructure theme.

Passive flow context: Program trading was a modest net +₩120bn; ETF net creation reached +₩1,151bn — a large inflow. But basis sits at −0.87, below the +1.0 threshold for passive-confirmed support. Large ETF inflows with negative basis suggest asset allocation rebalancing rather than directional conviction.

The session’s character: selective risk-off, with institutional rotation out of construction, batteries, and renewables into financials and infrastructure. In a Bear regime where only one in five stocks is above its 50-DMA, quality and earnings momentum are the few filters that matter.

3. Today’s Quality Re-Rating Candidates

Source: KR Meta Screener (2026-10-29), 88-ticker universe. The cross-screener overlap table shows no simple 2+ overlap pairs today; the meta screener ranks by independent evidence family count and family-capped scoring.

The framework’s editorial lens: good businesses where institutional money is entering and the market is beginning to reprice the earnings story.

Five names carry three or more independent evidence families. 티에프이 (425420.KQ) is the only name with all four layers — Quality Compounder + Smart Money Quality + Smart Money Earnings + Cycle Rerating — making it the highest-conviction setup in today’s screen.

Top Candidates

Rank	Ticker	Name	Meta Score	Families	Screeners Hit	Key Metrics
1	353200.KQ	Daedeok Electronics (대덕전자)	57.2	5	Quality, Cycle Rerating, PEAD	ROE 5.3%, OP YoY +336%, Δmargin +3.4pp
2	072950.KQ	Bitsaem Electronics (빛샘전자)	54.6	3	Quality, Cycle Rerating, PEAD	ROE 9.6%, OP YoY +77%, Δmargin +1.5pp
3	425420.KQ	TFE (티에프이)	54.5	4	Quality, Smart Money Quality, Smart Money Earnings, Cycle Rerating	ROE 16.6%, OP YoY +334%, Δmargin +11.1pp
4	086450.KQ	Dongkuk Pharma (동국제약)	54.4	5	Quality, Cycle Rerating, PEAD	ROE 9.9%, OP YoY +20%, Δmargin +0.5pp
5	080580.KQ	Okins Electronics (오킨스전자)	53.2	3	Quality, Cycle Rerating, PEAD	ROE 15.4%, OP YoY +482%, Δmargin +8.9pp
6	252990.KQ	SEM C&S (샘씨엔에스)	52.2	5	Quality, Cycle Rerating, PEAD	ROE 9.7%, OP YoY +183%, Δmargin +9.1pp ⚠️
7	089890.KQ	Cosses (코세스)	37.9	5	Cycle Rerating, PEAD, Consensus Up	Δmargin +29.2pp, DART contract catalyst
8	021240.KS	Coway (코웨이)	37.4	4	Quality, RS80 Not-Late	ROE 17.1%, earnings preview filed Oct 29
9	003380.KS	Harim Holdings (하림지주)	35.5	3	Cycle Rerating, RS80 Not-Late	Spin-off catalyst (DART Oct 26)
10	089860.KS	Lotte Rental (롯데렌탈)	34.5	3	Cycle Rerating, RS80 Not-Late	20D flow +11.2%, Focus Candidate

⚠️ 샘씨엔에스: Net foreign+institutional selling −₩17.4bn absorbed by retail +₩8.4bn. Monitor whether institutional selling persists post the Oct 27 preliminary earnings disclosure.

Deep-Dives: Top 3

1. Daedeok Electronics (대덕전자, 353200.KQ) — Operating Leverage Meets Official Catalyst

Daedeok is a PCB substrate manufacturer in Korea’s semiconductor packaging supply chain. Five independent evidence families at a meta score of 57.2 place it at the top of today’s queue. The operating leverage story is blunt: OP YoY +336%, margin expansion +3.4pp, with ROE rebuilding from a low base to 5.3%. The stock sits 27.6% below its 52-week high and 14.9% above the 50-DMA, leaving drift room intact. A DART IR event was filed Oct 23 — the catalyst layer is present. The caution is meaningful: net foreign+institutional selling of −₩6.3bn over five days signals sophisticated holders using strength to exit. The key question is whether the IR event reverses that flow or accelerates it.

2. TFE (티에프이, 425420.KQ) — All Four Layers, Institutional Absorption

TFE makes semiconductor test handler equipment. This is the only name today with the full four-layer stack — Quality Compounder, Smart Money Quality, Smart Money Earnings, and Cycle Rerating — which is the most complete signal structure the framework can produce. The fundamentals confirm it: ROE 16.6%, OP YoY +334%, and margin expansion of +11.1pp indicate a business deep in an earnings inflection. The flow pattern is equally clear: foreign and qualified institutional investors bought a net +₩14.3bn over five days while retail sold −₩15.8bn. That’s institutional accumulation against retail distribution — one of the framework’s cleanest money-flow setups. A large-holding disclosure was filed at DART on Oct 23. Next check: whether the five-day +₩14.3bn buying pace continues or was a block repositioning.

3. Dongkuk Pharmaceutical (동국제약, 086450.KQ) — Defensive Compounder in a Risk-Off Session

Dongkuk Pharmaceutical is a domestic pharma and nutraceutical company with a long record of steady compounding. It scores on five evidence families including fundamental quality, cycle rerating, and post-earnings drift. OP YoY at +20% is the lowest of the top five — but on a healthcare platform with recurring revenues, consistent margin expansion (+0.5pp) and ROE of 9.9% make it a defensive quality candidate. Foreign and institutional investors absorbed retail selling of −₩6.2bn, suggesting quiet accumulation. A shareholder meeting has been called (DART Oct 12); if strategic restructuring is on the agenda, the catalyst layer strengthens. In a session where construction and batteries are being sold indiscriminately, healthcare compounders with earnings improvement are a logical destination for repositioning capital.

Screener data as of 2026-10-29. Financial figures carry varying filing lags; most DART-sourced fundamentals are from Q4 2025 filings. These names are research candidates for further investigation, not investment recommendations.

Korea Quality Re-Rating Watch Oct 26: BioLogics, TFE, Bear Breadth

Mon, 26 Oct 2026 16:30:00 +0900

Macro Dashboard

Indicator	Level	5-Day Change	Signal
KOSPI	5,469.5	−1.5%	Flat
KOSDAQ	727.2	−7.0%	Weak
USD/KRW	1,324	−0.4%	Stable
VIX	19.67	+13.6%	Elevated
Brent	$109.92	+1.0%	Firm
US 10Y	4.99%	−15bp	Easing

KR Regime: Bear. Only 19.1% of tracked Korean equities trade above their 50-day moving average (out of 2,688 names). KOSDAQ’s 7% five-day slide is the primary driver.
US Regime: Bull. Nasdaq and S&P 500 remain above their 200-day MAs; VIX at 19.67 stays below the 20-point caution threshold; the 10Y/2Y curve holds at +31bp.
KR AA− corporate credit spread vs KTB 3Y: 69bp, broadly stable over the week.

Market Wrap

Source: KR Market Snapshot DB (2026-10-26). No same-day full close briefing was generated; this section draws from the close-of-day market database.

October 26 was a broad selloff with little place to hide. Of 2,593 tracked Korean equities, 1,928 declined and only 447 advanced — an ADR proxy of 23.2% and an average stock return of −1.75%. That is bear-market breadth, not selective sector rotation.

The headline KOSPI/KOSDAQ divergence carries the week’s clearest signal. KOSPI is down 1.5% over five sessions; KOSDAQ is down 7.0%. The gap points to sustained selling in small- and mid-cap growth: semiconductor equipment, KOSDAQ tech hardware, and select consumer names absorbed the heaviest damage. Large-cap defensives and IT services held comparatively better.

Passive outflows amplified the pressure. ETF net redemptions totaled −₩1.18 trillion, with market program net selling at −₩527bn. The futures basis sat at −1.51 — deeply negative — flagging limited demand for leveraged index exposure.

Foreign flow was fragmented. Foreigners net-bought into weakness on 두산 (000150.KS, −6.5%), S-Oil (010950.KS, −3.6%), NAVER (035420.KS, +0.4%), and 삼성E&A (028050.KS). They were net sellers across financials — BNK금융지주 (138930.KS, −13.8%), KB금융 (105560.KS, −3.8%), 우리금융지주 (316140.KS, −2.8%) — and sold out of 삼성에스디에스 (018260.KS) and LG씨엔에스 (064400.KS) in IT services.

Institutions moved in the opposite direction on those IT services names, net-buying 삼성에스디에스, LG씨엔에스, 삼성생명 (032830.KS), and 삼성물산 (028260.KS) while foreigners sold. Domestic institutions absorbing foreign supply in large-cap IT services was one of the few conviction flows on the session. Elsewhere, institutions sold cyclicals and energy: 한화솔루션 (009830.KS, −6.9%), 피에스케이 (319660.KS, −7.2%), 삼양식품 (003230.KS, −8.9%), and HPSP (403870.KQ, −5.9%).

The overall character: risk-off, broad-based, and KOSDAQ-led. Semiconductor equipment, regional banks, energy, and consumer discretionary absorbed the brunt. The session was not selective — it was a tide going out.

Today’s Quality Re-Rating Candidates

Source: KR Meta Screener (2026-10-26, all screener sources fresh). The Screener Intersection Summary included only PEAD for today’s raw-overlap table and returned no 2+ screener matches; the Meta Screener synthesizes quality, smart money, cycle rerating, earnings, consensus revision, RS80, and official DART signals across a 111-ticker candidate universe.

Despite the broad selloff, the meta screener surfaces names where institutional and foreign capital is entering against retail supply — the exact setup this framework is designed to flag.

Top Screened Candidates

Rank	Ticker	Name	Meta Score	Evidence Families	Key Screener Signals	Key Metrics
1	207940.KS	Samsung BioLogics	56.3	5	Cycle Rerating, PEAD, SM Earnings, SM Quality	OPM 45.4%, Δmargin +7.6pp, F+QI net buy +₩125bn (5D)
2	425420.KQ	TFE	49.3	3	Quality Compounder, Cycle Rerating, SM Earnings, SM Quality	ROE 16.6%, OP YoY +334%, Δmargin +11.1pp
3	089890.KQ	Koses	48.1	4	Cycle Rerating, Consensus Up, SM Quality	Δmargin +29.2pp, F+QI net buy +₩17bn (5D)
4	086450.KS	Dong Kook Pharm	44.5	3	Quality Compounder, Cycle Rerating	ROE 9.9%, OP YoY +20.1%, Δmargin +0.5pp
5	003350.KS	Korea Cosmetics Mfg	43.1	4	Quality Compounder, Cycle Rerating, SM Earnings, SM Quality	ROE 30.6%, OP YoY +24.2%, Δmargin +2.0pp
6	021240.KS	Coway	40.3	4	Quality Compounder, RS80 Not-Late	ROE 17.1%, OP YoY +10.5%, pivot gap +8.2%
7	068270.KS	Celltrion	38.7	4	Cycle Rerating, RS80 Not-Late	Δmargin +14.2pp, 5× DART catalyst filings
8	089860.KS	Lotte Rental	35.8	4	Cycle Rerating, RS80 Not-Late	Δmargin +0.5pp, earnings preview DART filed
9	098120.KQ	Microcontact Sol	34.6	5	SM Earnings, SM Quality, Kiwoom Surface	F+QI net buy +₩3.5bn (5D)
10	420770.KQ	Gigavis	34.4	5	SM Earnings, SM Quality, PEAD	F+QI net sell −₩3.3bn absorbed by retail +₩3.7bn

SM = Smart Money. All data as of 2026-10-26. Note: Gigavis (420770.KQ) shows institutional/foreign net selling absorbed by retail — the inversion of the preferred setup; treat with caution.

Top 3 in Focus

Samsung BioLogics (207940.KS) — Meta Rank #1 Korea’s largest contract drug manufacturer. The meta screener ranks it first not on the Quality Compounder signal alone, but because all five independent evidence families are firing together: the earnings-cycle axis (OPM expanded 7.6pp to 45.4%), PEAD (price still adjusting to the last earnings print), smart money quality (foreigners and quality institutions net-bought ₩125bn over five days while retail distributed ₩84bn), and DART filings (three insider ownership reports filed Oct 26). The key question to verify next: whether the operating margin expansion reflects structural capacity-utilization improvement in biologics CDMO contracts, or a one-period mix shift.

TFE (425420.KQ) — Meta Rank #2 A semiconductor and display equipment components maker that clears every primary screen simultaneously — the only name in the top-10 with Quality Compounder, Cycle Rerating, Smart Money Quality, and Smart Money Earnings all active. Operating profit grew 334% YoY with margin expanding 11.1pp; ROE stands at 16.6%. Foreign and quality institutional investors net-bought ₩24bn against retail selling ₩38bn over five days. Its raw meta score (77.6) is the highest in the table; the family-adjusted score (49.3) is lower because the scoring caps same-family evidence to avoid double-counting correlated signals. Next check: determine whether the earnings base was abnormally depressed a year ago, or whether the margin inflection reflects a durable product-mix or utilization shift.

Korea Cosmetics Manufacturing (003350.KS) — Meta Rank #6, three primary signals active An OEM/ODM cosmetics formulator running the highest ROE in the top-10 at 30.6%. Operating profit grew 24.2% YoY with 2pp of margin expansion, and smart money is net-buying over five days (F+QI +₩31bn vs retail −₩27bn). Like TFE, it clears all three primary screens: Quality Compounder, Cycle Rerating, and Smart Money Quality — which is why it deserves attention above its raw rank of sixth. One caution flags in the DART overlay: a convertible-right exercise was filed on Oct 7, classified as a risk disclosure. The next check is whether the potential dilution is material relative to the earnings trajectory that drove the screener inclusion.